Meningococcal Disease: Clinical Trials

20 trials for Meningococcal Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

20 completed. 20 Phase 2, 3 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 220Completed 20
Phase 33Completed 3
Phase 11Completed 1

Follow Meningococcal Disease: new trials by email Literature Review of Meningococcal Disease trials Research Report on Meningococcal Disease

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)
MenABCWY+OMV vaccine - Meningococcal Disease, Infections, Meningococcal
Phase 2CompletedGlaxoSmithKline1292015-06-302020-07-09
Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
Meningococcal ABCWY, Placebo - Meningococcal Disease
Phase 2CompletedGlaxoSmithKline1892014-12-012018-09-24
Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
MenABCWY, Placebo, MenACWY - Meningococcal Disease
Phase 2CompletedNovartis Vaccines3052014-05-012018-09-12
Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)
MenABCWY+OMV, MenABCWY+¼OMV, Placebo - Meningococcal Disease
Phase 2CompletedNovartis Vaccines1942013-12-012016-10-25
Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers
MenACWY-CRM, MenACWY-TT - Meningococcal Disease
Phase 2CompletedNovartis Vaccines2022013-11-012015-11-04
Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines
MEN-ACYW135 reduced-dose intradermal administration - Meningococcal Disease
Phase 1 / Phase 2CompletedLeiden University Medical Center122013-01-012014-10-29
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers
MenC-CRM LIQ, MenC-CRM ROS, MenC-CRM EMV - Meningococcal Disease, Meningococcal Meningitis
Phase 2CompletedNovartis9922011-09-012017-04-25
Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Tdap - Meningococcal Disease, Meningococcal Meningitis
Phase 2CompletedNovartis Vaccines4402011-07-012014-11-19
Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents
Meningococcal Vaccine - Meningococcal Disease, Meningococcal Meningitis
Phase 2CompletedNovartis Vaccines4952010-12-012011-10-24
Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10
No Vaccine, rMenB+OMV-NZ - Meningococcal Disease, Meningococcal Meningitis
Phase 2 / Phase 3CompletedNovartis Vaccines8172010-08-012018-06-15
Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine
rMenB, rMenB+OMV NZ - Meningococcal Disease
Phase 2CompletedNovartis Vaccines1202010-02-012014-10-01
Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine
Meningococcal (group B) multicomponent recombinant adsorbed vaccine., Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV) - Meningococcal Disease
Phase 2CompletedNovartis Vaccines1632010-01-012018-10-09
A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY
Novartis Meningococcal (MenACWY-CRM) vaccine - Meningococcal Disease, Meningococcal Meningitis
Phase 2CompletedNovartis Vaccines1552010-01-012015-07-15
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12
rMenB+OMV NZ with routine vaccinations, rMenB+OMV NZ, two doses of rMenB+OMV NZ - Meningococcal Disease, Meningococcal Meningitis
Phase 2 / Phase 3CompletedNovartis Vaccines15882009-07-012017-08-14
Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules
rMenB+OMV NZ, Placebo - Meningococcal Disease
Phase 2 / Phase 3CompletedNovartis Vaccines16312008-06-012019-03-20
Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months
MenACWY-CRM197, Blood test - Meningococcal Disease
Phase 2CompletedNovartis Vaccines3822008-02-012014-10-24
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults
Men ACWY CRM, 4CMenB - Meningococcal Disease
Phase 2CompletedNovartis Vaccines542007-07-012016-04-01
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
MenACWY-CRM, DTaP-Hib-IPV, PCV - Meningococcal Disease
Phase 2CompletedNovartis Vaccines2162007-07-012014-10-01
Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants
rMenB, rMenB+OMV - Meningococcal Disease
Phase 2CompletedNovartis Vaccines602007-02-012015-03-06
Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents
serogroup B meningococcal vaccine - Meningococcal Disease
Phase 2CompletedNovartis Vaccines2032006-02-012016-12-01

Narrower conditions

Meningococcal Infections (20)  ·  Meningitis, Meningococcal (7)  ·  Meningitis (3)

Broader conditions

Bacterial Infections (20)  ·  Bacterial Infections and Mycoses (20)  ·  Gram-Negative Bacterial Infections (20)  ·  Infections (20)  ·  Neisseriaceae Infections (20)  ·  Central Nervous System Bacterial Infections (7)  ·  Central Nervous System Diseases (7)  ·  Central Nervous System Infections (7)  ·  Meningitis, Bacterial (7)  ·  Nervous System Diseases (7)  ·  Neuroinflammatory Diseases (7)  ·  Meningitis (4)

Interventions

4CMenB vaccine (3)  ·  Meningococcal Vaccines (3)  ·  MenACWY-CRM vaccine (2)  ·  Hematologic Tests (1)  ·  Heptavalent Pneumococcal Conjugate Vaccine (1)  ·  Measles-Mumps-Rubella Vaccine (1)  ·  MenACWY (1)  ·  Poliovirus Vaccine, Inactivated (1)  ·  Rubella Vaccine (1)  ·  Saline Solution (1)  ·  Tetanus Toxoid (1)  ·  Vaccines (1)  ·  diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine (1)  ·  tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (1)

Sponsors

Novartis Vaccines (16)  ·  GlaxoSmithKline (2)  ·  Leiden University Medical Center (1)  ·  Novartis (1)

Countries

United Kingdom (6)  ·  Chile (5)  ·  United States (5)  ·  Colombia (3)  ·  Italy (3)  ·  Panama (3)  ·  Poland (2)  ·  Belgium (1)  ·  Canada (1)  ·  Czechia (1)  ·  Germany (1)  ·  Netherlands (1)  ·  Spain (1)

Top investigators

Leo Visser, MD, PhD (1)

Results publications

PMID 33020485, PMID 35257644, PMID 21177912, PMID 30061029, PMID 20844462, PMID 22260988, PMID 22394992, PMID 23114372, PMID 23566945, PMID 23958808, PMID 24062178, PMID 25802309, PMID 25969894, PMID 26135245, PMID 26756390, PMID 29778515

NIH funding

2009 (1), 2016 (1)